Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.

Amit M. Algotar, Steven P Stratton, James Ranger-Moore, M. Suzanne Stratton, Chiu-Hsieh Hsu, Frederick R Ahmann, Raymond B Nagle, Patricia A. Thompson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Significant number of prostate tumors are slow growing and could probably be left untreated. However, many are aggressive and can spread rapidly causing patient suffering and/or death. Current technology does not allow physicians to differentiate between slow growing and aggressive tumors at diagnosis. Hence, many patients are exposed to invasive treatment and its associated morbidities such as incontinence and impotence. Markers that enable differentiation between slow and fast progressing cancer will allow physicians to prevent unnecessary treatments on men who may not need them, and focus on the men with aggressive disease. A longitudinal study was conducted (N = 140) using mixed effects regression models to determine the association of obesity and smoking toward prostate cancer progression. These models account for correlation because of repeated measures over time, thus, using maximum amount of information provided by the subject. Estimates thus obtained are more robust and reliable than those obtained using data from a single time point. Rate of change of prostate-specific antigen (PSA) over time (PSA velocity) was used as a measure of prostate cancer progression. Results indicate that PSA velocity of overweight and obese subjects (0.59 and 1.05 ng/mL/year) was not significantly different as compared with normal weight subjects (p values .91 and .31, respectively). For men in the highest tertile of pack-years of smoking, PSA velocity was significantly higher as compared with never smokers 1.57 ng/mL/year (p = .04). Further studies with larger sample sizes and study designs specific to above exposures are needed before recommendations can be made to reduce weight or reduce/quit smoking.

Original languageEnglish (US)
Pages (from-to)272-278
Number of pages7
JournalAmerican Journal of Men's Health
Volume5
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Prostate-Specific Antigen
smoking
Prostatic Neoplasms
cancer
Obesity
Smoking
physician
Physicians
Weights and Measures
Neoplasms
morbidity
Differentiation Antigens
longitudinal study
Erectile Dysfunction
Psychological Stress
Sample Size
Disease
death
Longitudinal Studies
Prostate

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health(social science)

Cite this

Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer. / Algotar, Amit M.; Stratton, Steven P; Ranger-Moore, James; Stratton, M. Suzanne; Hsu, Chiu-Hsieh; Ahmann, Frederick R; Nagle, Raymond B; Thompson, Patricia A.

In: American Journal of Men's Health, Vol. 5, No. 3, 05.2011, p. 272-278.

Research output: Contribution to journalArticle

@article{1704346906754cfb94b91aaf8fcefc30,
title = "Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.",
abstract = "Significant number of prostate tumors are slow growing and could probably be left untreated. However, many are aggressive and can spread rapidly causing patient suffering and/or death. Current technology does not allow physicians to differentiate between slow growing and aggressive tumors at diagnosis. Hence, many patients are exposed to invasive treatment and its associated morbidities such as incontinence and impotence. Markers that enable differentiation between slow and fast progressing cancer will allow physicians to prevent unnecessary treatments on men who may not need them, and focus on the men with aggressive disease. A longitudinal study was conducted (N = 140) using mixed effects regression models to determine the association of obesity and smoking toward prostate cancer progression. These models account for correlation because of repeated measures over time, thus, using maximum amount of information provided by the subject. Estimates thus obtained are more robust and reliable than those obtained using data from a single time point. Rate of change of prostate-specific antigen (PSA) over time (PSA velocity) was used as a measure of prostate cancer progression. Results indicate that PSA velocity of overweight and obese subjects (0.59 and 1.05 ng/mL/year) was not significantly different as compared with normal weight subjects (p values .91 and .31, respectively). For men in the highest tertile of pack-years of smoking, PSA velocity was significantly higher as compared with never smokers 1.57 ng/mL/year (p = .04). Further studies with larger sample sizes and study designs specific to above exposures are needed before recommendations can be made to reduce weight or reduce/quit smoking.",
author = "Algotar, {Amit M.} and Stratton, {Steven P} and James Ranger-Moore and Stratton, {M. Suzanne} and Chiu-Hsieh Hsu and Ahmann, {Frederick R} and Nagle, {Raymond B} and Thompson, {Patricia A.}",
year = "2011",
month = "5",
doi = "10.1177/1557988310390030",
language = "English (US)",
volume = "5",
pages = "272--278",
journal = "American Journal of Men's Health",
issn = "1557-9883",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.

AU - Algotar, Amit M.

AU - Stratton, Steven P

AU - Ranger-Moore, James

AU - Stratton, M. Suzanne

AU - Hsu, Chiu-Hsieh

AU - Ahmann, Frederick R

AU - Nagle, Raymond B

AU - Thompson, Patricia A.

PY - 2011/5

Y1 - 2011/5

N2 - Significant number of prostate tumors are slow growing and could probably be left untreated. However, many are aggressive and can spread rapidly causing patient suffering and/or death. Current technology does not allow physicians to differentiate between slow growing and aggressive tumors at diagnosis. Hence, many patients are exposed to invasive treatment and its associated morbidities such as incontinence and impotence. Markers that enable differentiation between slow and fast progressing cancer will allow physicians to prevent unnecessary treatments on men who may not need them, and focus on the men with aggressive disease. A longitudinal study was conducted (N = 140) using mixed effects regression models to determine the association of obesity and smoking toward prostate cancer progression. These models account for correlation because of repeated measures over time, thus, using maximum amount of information provided by the subject. Estimates thus obtained are more robust and reliable than those obtained using data from a single time point. Rate of change of prostate-specific antigen (PSA) over time (PSA velocity) was used as a measure of prostate cancer progression. Results indicate that PSA velocity of overweight and obese subjects (0.59 and 1.05 ng/mL/year) was not significantly different as compared with normal weight subjects (p values .91 and .31, respectively). For men in the highest tertile of pack-years of smoking, PSA velocity was significantly higher as compared with never smokers 1.57 ng/mL/year (p = .04). Further studies with larger sample sizes and study designs specific to above exposures are needed before recommendations can be made to reduce weight or reduce/quit smoking.

AB - Significant number of prostate tumors are slow growing and could probably be left untreated. However, many are aggressive and can spread rapidly causing patient suffering and/or death. Current technology does not allow physicians to differentiate between slow growing and aggressive tumors at diagnosis. Hence, many patients are exposed to invasive treatment and its associated morbidities such as incontinence and impotence. Markers that enable differentiation between slow and fast progressing cancer will allow physicians to prevent unnecessary treatments on men who may not need them, and focus on the men with aggressive disease. A longitudinal study was conducted (N = 140) using mixed effects regression models to determine the association of obesity and smoking toward prostate cancer progression. These models account for correlation because of repeated measures over time, thus, using maximum amount of information provided by the subject. Estimates thus obtained are more robust and reliable than those obtained using data from a single time point. Rate of change of prostate-specific antigen (PSA) over time (PSA velocity) was used as a measure of prostate cancer progression. Results indicate that PSA velocity of overweight and obese subjects (0.59 and 1.05 ng/mL/year) was not significantly different as compared with normal weight subjects (p values .91 and .31, respectively). For men in the highest tertile of pack-years of smoking, PSA velocity was significantly higher as compared with never smokers 1.57 ng/mL/year (p = .04). Further studies with larger sample sizes and study designs specific to above exposures are needed before recommendations can be made to reduce weight or reduce/quit smoking.

UR - http://www.scopus.com/inward/record.url?scp=80052090083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052090083&partnerID=8YFLogxK

U2 - 10.1177/1557988310390030

DO - 10.1177/1557988310390030

M3 - Article

VL - 5

SP - 272

EP - 278

JO - American Journal of Men's Health

JF - American Journal of Men's Health

SN - 1557-9883

IS - 3

ER -